Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -1.55%85 3-Year EBITDA Growth Rate is 14.00% as of Mar. 2026, which is 94% above its 10-year median of 7.20. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT128.93 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 808 Drug Manufacturers companies, ACME Laboratories ranks better than 58.54% on this metric.
During the past 12 months, ACME Laboratories's average EBITDA Per Share Growth Rate was 13.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of ACME Laboratories was 14.00% per year. The lowest was 5.10% per year. And the median was 7.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ACME Laboratories 3-Year EBITDA Growth Rate Related Terms
DHA:ACMELAB vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.00% mean?
ACME Laboratories (DHA:ACMELAB) has a 3-Year EBITDA Growth Rate of 14.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ACME Laboratories and its competitors. This is 94% above median its historical median of 7.20. Over the past decade, ACME Laboratories' 3-Year EBITDA Growth Rate has ranged from 5.10 to 14.00. According to the industry distribution chart, ACME Laboratories ranks #335 out of 808 companies in the Drug Manufacturers industry, placing it in the top 41.5%.
Is ACME Laboratories' 3-Year EBITDA Growth Rate too high?
ACME Laboratories' current 3-Year EBITDA Growth Rate of 14.00% is 94% above median its 10-year median of 7.20. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 14.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. ACME Laboratories' value of 14.00% is 57.3% above this industry median. Based on the distribution chart, ACME Laboratories ranks #335 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #335 out of 808 companies for 3-Year EBITDA Growth Rate. This puts ACME Laboratories in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. ACME Laboratories' value of 14.00% is 57.3% above this benchmark. Historically, ACME Laboratories' own 3-Year EBITDA Growth Rate has ranged from 5.10 to 14.00 over the past decade. While the company's 10-year median is 7.20 vs. the industry median of 8.90, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current 3-Year EBITDA Growth Rate of 14.00% is 57.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current 3-Year EBITDA Growth Rate is 14.00%, which is 94% above median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT128.93, compared to a current price of BDT76.30 — trading 40.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.00%, which is 94% above median its 10-year median of 7.20 and 57.3% above the Drug Manufacturers industry median of 8.90. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current 3-Year EBITDA Growth Rate is 14.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT76.30 is trading 40.8% below its estimated GF Value™ of BDT128.93.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
3-Year EBITDA Growth Rate: 14.00% (94% above median its 10-year median of 7.20)
GF Value™: BDT128.93 vs. price of BDT76.30 (40.8% below fair value)
Industry Position: 57.3% above the Drug Manufacturers median (#335 of 808)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
